The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.

The company reckons it’s got what it takes to hit the right member of the FGFR family.

Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.